News >

Rituximab and Trastuzumab Biosimilars Shown to Have Economic Advantage Over Originators

Ellie Leick
Published: Friday, Nov 01, 2019

An analysis of the economic impact of biosimilars in oncology and hematology found that biosimilars for rituximab (Rituxan) and trastuzumab (Herceptin) offer economic benefit compared with their reference drugs as first-line treatment in follicular lymphoma and as neoadjuvant breast cancer treatment, respectively, explained Jacopo Giuliani, MD.

[There are] potentially different monoclonal antibodies and granulocyte [colony stimulating] factors.
Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019;39(7):3971-3973. doi: 10.21873/anticanres.13552.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication